GlaxoSmithKline and AbbVie Inc. offer market beating dividend yields, but AbbVie may be the better buy.
It's been proven time and time again
that long term investing is better than short term trading and it's been
shown that dividend paying companies outperform their non-dividend
paying peers, but not every dividend stock is worthy of owning in
portfolios. For example, a high dividend yield may not be justification
enough to own shares in a company that's business isn't on solid ground.
Although there are hundreds of dividend paying stocks to choose from, let's begin by looking at GlaxoSmithKline (NYSE:GSK) and AbbVie (NYSE:ABBV), two healthcare giants that pay investors above market dividend yields of 6.6% and 4%, respectively. Is one a better buy than the other?
Let's check out...
Source: The Motley Fool
Although there are hundreds of dividend paying stocks to choose from, let's begin by looking at GlaxoSmithKline (NYSE:GSK) and AbbVie (NYSE:ABBV), two healthcare giants that pay investors above market dividend yields of 6.6% and 4%, respectively. Is one a better buy than the other?
Let's check out...
Source: The Motley Fool